April 2015

New Product - Zydelig

Zydelig (idelalisib) inhibits PI3Kdelta, which is hyperactive in B‑cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing, and retention of malignant cells in lymphoid tissues and bone marrow. Idelalisib is a selective inhibitor of adenosine‑5’‑triphosphate (ATP) binding to the catalytic domain of PI3Kdelta, resulting in inhibition of the phosphorylation of the key lipid second messenger phosphatidylinositol (PIP) and prevention of Akt phosphorylation. Zydelig in combination with rituximab is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) for whom chemo‑immunotherapy is not considered suitable, either upon relapse after at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation. Zydelig is indicated as monotherapy for the treatment of patients with refractory follicular lymphoma who have received at least two prior systemic therapies. Zydelig is available as 100 mg and 150 mg tablets in bottles of 60’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629